Bio-Images Research appoints director of regulatory affairs

To maintain highest level of ethical standards as firm expands

Clinical research firm Bio-Images Research has appointed a director of regulatory affairs.

Dr Sarah Connolly, who has been with the Glasgow-based company for the past four years, will take responsibility for GMP, regulatory and ethical approvals.

The appointment is designed to maintain the highest level of ethical and regulatory standards as the company's pipeline of clinical studies steadily increases.

Bio-Images has completed three clinical studies this year and claims to be in the forefront of a small field of providers of gamma scintigraphy imaging services, which allow multi-national pharma companies to outsource some of their clinical research.

Dr Connolly joined the company after completing her PhD in Pharmaceutical Sciences at the University of Strathclyde in 2007.

You may also like

Regulatory

Bio-Images Group and CPS Research form partnership

Glasgow firms will combine formulation development and clinical trial capabilities
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Regulatory

Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial

The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

From approval to access: the strategic role of packaging in drug launch success

In today’s increasingly complex pharmaceutical landscape, securing regulatory approval is only one milestone on the journey to market
Research & Development

Servier acquires potential treatment for Fragile X syndrome

KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
Subscribe now